NURIX THERAPEUTICS, INC. Capital Expenditures
NURIX THERAPEUTICS, INC. (NRIX) reported Capital Expenditures of $2.98 million for the 6-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-05-31 was $1.94M, a 27.63% decline year-over-year.
- NURIX THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-02-28 was $1.04M, a 70.01% decline year-over-year.
- NURIX THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-11-30 was $5.13M, a 143.75% increase year-over-year.
- NURIX THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-08-31 was $2.71M, a 15.51% increase year-over-year.
- NURIX THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $14.00M, a 51.00% increase from fiscal 2024.
- NURIX THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $9.27M, a 10.38% increase from fiscal 2023.
- NURIX THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $8.40M, a 31.39% decline from fiscal 2022.
- NURIX THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $12.24M, a 116.29% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-05-31 | $1.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $2.98M 10-Q · filed 2026-07-09 | $8.11M derived: sum of 3 quarters · filed 2026-07-09 | $10.82M derived: sum of 4 quarters · filed 2026-07-09 |
| 2026-02-28 | $1.04M 10-Q · filed 2026-04-08 | $6.18M derived: sum of 2 quarters · filed 2026-04-08 | $8.89M derived: sum of 3 quarters · filed 2026-04-08 | $11.56M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-11-30 | $5.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $7.84M derived: sum of 2 quarters · filed 2026-01-28 | $10.52M derived: sum of 3 quarters · filed 2026-07-09 | $14.00M 10-K · filed 2026-01-28 |
| 2025-08-31 | $2.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | $5.39M derived: sum of 2 quarters · filed 2026-07-09 | $8.87M 10-Q · filed 2025-10-09 | $10.98M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-05-31 | $2.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $6.16M 10-Q · filed 2026-07-09 | $8.27M derived: sum of 3 quarters · filed 2026-07-09 | $10.61M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-02-28 | $3.48M 10-Q · filed 2026-04-08 | $5.59M derived: sum of 2 quarters · filed 2026-04-08 | $7.94M derived: sum of 3 quarters · filed 2026-04-08 | $9.87M derived: sum of 4 quarters · filed 2026-04-08 |
| 2024-11-30 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $4.45M derived: sum of 2 quarters · filed 2026-01-28 | $6.39M derived: sum of 3 quarters · filed 2026-01-28 | $9.27M 10-K · filed 2026-01-28 |
| 2024-08-31 | $2.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | $4.28M derived: sum of 2 quarters · filed 2025-10-09 | $7.17M 10-Q · filed 2025-10-09 | $9.75M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-05-31 | $1.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-09 | $4.82M 10-Q · filed 2025-07-09 | $7.41M derived: sum of 3 quarters · filed 2026-01-28 | $9.87M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-02-29 | $2.88M 10-Q · filed 2025-04-08 | $5.47M derived: sum of 2 quarters · filed 2026-01-28 | $7.93M derived: sum of 3 quarters · filed 2026-01-28 | $9.01M derived: sum of 4 quarters · filed 2026-01-28 |
| 2023-11-30 | $2.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $5.04M derived: sum of 2 quarters · filed 2026-01-28 | $6.12M derived: sum of 3 quarters · filed 2026-01-28 | $8.40M 10-K · filed 2026-01-28 |
| 2023-08-31 | $2.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-11 | $3.54M derived: sum of 2 quarters · filed 2024-10-11 | $5.82M 10-Q · filed 2024-10-11 | $8.38M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-05-31 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-11 | $3.36M 10-Q · filed 2024-07-11 | $5.92M derived: sum of 3 quarters · filed 2025-01-28 | $9.34M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-02-28 | $2.28M 10-Q · filed 2024-04-10 | $4.84M derived: sum of 2 quarters · filed 2025-01-28 | $8.26M derived: sum of 3 quarters · filed 2025-01-28 | $11.05M derived: sum of 4 quarters · filed 2025-01-28 |
| 2022-11-30 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | $5.98M derived: sum of 2 quarters · filed 2025-01-28 | $8.77M derived: sum of 3 quarters · filed 2025-01-28 | $12.24M 10-K · filed 2025-01-28 |
| 2022-08-31 | $3.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-12 | $6.21M derived: sum of 2 quarters · filed 2023-10-12 | $9.68M 10-Q · filed 2023-10-12 | $10.54M derived: sum of 4 quarters · filed 2023-10-12 |
| 2022-05-31 | $2.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-13 | $6.26M 10-Q · filed 2023-07-13 | $7.12M derived: sum of 3 quarters · filed 2023-07-13 | $8.99M derived: sum of 4 quarters · filed 2023-07-13 |
| 2022-02-28 | $3.47M 10-Q · filed 2023-04-13 | $4.33M derived: sum of 2 quarters · filed 2023-04-13 | $6.20M derived: sum of 3 quarters · filed 2023-04-13 | $8.29M derived: sum of 4 quarters · filed 2023-04-13 |
| 2021-11-30 | $862.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $2.73M derived: sum of 2 quarters · filed 2023-02-09 | $4.82M derived: sum of 3 quarters · filed 2023-02-09 | $5.66M 10-K · filed 2023-02-09 |
| 2021-08-31 | $1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-06 | $3.96M derived: sum of 2 quarters · filed 2022-10-06 | $4.80M 10-Q · filed 2022-10-06 | $5.71M derived: sum of 4 quarters · filed 2022-10-06 |
| 2021-05-31 | $2.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07 | $2.93M 10-Q · filed 2022-07-07 | $3.84M derived: sum of 3 quarters · filed 2022-07-07 | $5.51M derived: sum of 4 quarters · filed 2022-07-07 |
| 2021-02-28 | $843.00K 10-Q · filed 2022-04-08 | $1.75M derived: sum of 2 quarters · filed 2022-04-08 | $3.42M derived: sum of 3 quarters · filed 2022-04-08 | $5.03M derived: sum of 4 quarters · filed 2022-04-08 |
| 2020-11-30 | $906.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $2.58M derived: sum of 2 quarters · filed 2022-01-28 | $4.19M derived: sum of 3 quarters · filed 2022-01-28 | $4.55M 10-K · filed 2022-01-28 |
| 2020-08-31 | $1.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-14 | $3.28M derived: sum of 2 quarters · filed 2021-10-14 | $3.65M 10-Q · filed 2021-10-14 | $4.60M derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-05-31 | $1.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-13 | $1.98M 10-Q · filed 2021-07-13 | $2.93M derived: sum of 3 quarters · filed 2022-01-28 | |
| 2020-02-29 | $364.00K 10-Q · filed 2021-04-13 | $1.32M derived: sum of 2 quarters · filed 2022-01-28 | ||
| 2019-11-30 | $953.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $1.65M 10-K · filed 2022-01-28 | ||
| 2019-08-31 | $698.00K 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |